39 related articles for article (PubMed ID: 10215399)
1. Peptide immobilized on gold particles enhances cell growth.
Gong J; Ito Y
Cytotechnology; 2008 Nov; 58(3):141-4. PubMed ID: 19137449
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-induced expansion of human CD34+ stem/progenitor and CD34+CD41+ early megakaryocytic marrow cells cultured on normal osteoblasts.
Ahmed N; Khokher MA; Hassan HT
Stem Cells; 1999; 17(2):92-9. PubMed ID: 10195569
[TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant human thrombopoietin alone and in combination with erythropoietin and early-acting cytokines on human mobilized purified CD34+ progenitor cells cultured in serum-depleted medium.
Birkmann J; Oez S; Smetak M; Kaiser G; Kappauf H; Gallmeier WM
Stem Cells; 1997; 15(1):18-32. PubMed ID: 9007219
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 and interleukin-11 act synergistically with thrombopoietin and stem cell factor to modulate ex vivo expansion of human CD41+ and CD61+ megakaryocytic cells.
Lazzari L; Henschler R; Lecchi L; Rebulla P; Mertelsmann R; Sirchia G
Haematologica; 2000 Jan; 85(1):25-30. PubMed ID: 10629587
[TBL] [Abstract][Full Text] [Related]
6. c-kit ligand combined with GM-CSF and/or IL-3 can expand CD34+ hematopoietic progenitor subsets for several weeks in vitro.
Steen R; Mørkrid L; Tjønnfjord GE; Egeland T
Stem Cells; 1994 Mar; 12(2):214-24. PubMed ID: 7515297
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin combined with early-acting growth factors effectively expands human hematopoietic progenitor cells in vitro.
Hunnestad JA; Steen R; Tjønnfjord GE; Egeland T
Stem Cells; 1999; 17(1):31-8. PubMed ID: 10215399
[TBL] [Abstract][Full Text] [Related]
8. Do the preclinical effects of thrombopoietin correlate with its in vitro properties?
Kaushansky K; Broudy VC; Sitnicka E; Lofton-Day C; Grossmann A; Sprugel K
Stem Cells; 1996; 14 Suppl 1():108-11. PubMed ID: 11012209
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin: more than a lineage-specific megakaryocyte growth factor.
Kaushansky K
Stem Cells; 1997; 15 Suppl 1():97-102; discussion 102-3. PubMed ID: 9368329
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin: biology and clinical potentials.
Miyazaki H; Kato T
Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation.
Wagemaker G; Neelis KJ; Hartong SC; Wognum AW; Thomas GR; Fielder PJ; Eaton DL
Stem Cells; 1998; 16(6):375-86. PubMed ID: 9831863
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo expansion of hematopoietic progenitor cells for clinical use.
Scheding S; Kratz-Albers K; Meister B; Brugger W; Kanz L
Semin Hematol; 1998 Jul; 35(3):232-40. PubMed ID: 9685169
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
